Compare ADUS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADUS | BEAM |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2009 | 2020 |
| Metric | ADUS | BEAM |
|---|---|---|
| Price | $107.29 | $27.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $138.73 | $48.09 |
| AVG Volume (30 Days) | 154.5K | ★ 1.6M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.76 | N/A |
| EPS | ★ 4.66 | N/A |
| Revenue | ★ $1,346,596,000.00 | $55,701,000.00 |
| Revenue This Year | $25.50 | N/A |
| Revenue Next Year | $7.11 | $26.52 |
| P/E Ratio | $23.04 | ★ N/A |
| Revenue Growth | ★ 18.77 | N/A |
| 52 Week Low | $88.96 | $13.53 |
| 52 Week High | $136.72 | $35.25 |
| Indicator | ADUS | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 33.21 | 53.35 |
| Support Level | $110.12 | $26.71 |
| Resistance Level | $111.57 | $28.00 |
| Average True Range (ATR) | 2.24 | 1.23 |
| MACD | -0.60 | -0.08 |
| Stochastic Oscillator | 16.68 | 47.95 |
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, mainly to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are medical in nature to those individuals who may require assistance during an illness or after surgery.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.